Steffen Luntz

机构：Heidelberg University, University Hospital Heidelberg, Heidelberg University · ORCID：0000-0002-4696-8792

发表论文 72 篇 · 总被引 2489 次 · h-index 21

代表论文

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial (2022 · The Lancet Haematology · 被引 156)
The impact of COVID-19 related lockdown measures on self-reported psychopathology and health-related quality of life in German adolescents (2021 · European Child & Adolescent Psychiatry · 被引 70)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial (2024 · Journal of Clinical Oncology · 被引 68)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE (2020 · Leukemia · 被引 67)
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021 · Blood Cancer Journal · 被引 33)
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial (2021 · Blood · 被引 32)